HARS1/Jo-1 antibody (C-Term)

Catalog No. ABIN7180180

This anti-HARS1/Jo-1 antibody is a Rabbit Polyclonal antibody detecting HARS1/Jo-1 in WB, ELISA and IF. Suitable for Human.

Quick Overview for HARS1/Jo-1 antibody (C-Term) (ABIN7180180)

Target: HARS1/Jo-1 (HARS1) (Histidyl-tRNA Synthetase (HARS1))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HARS1/Jo-1 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunofluorescence (IF)

Product Details anti-HARS1/Jo-1 Antibody

Binding Specificity: C-Term

Cross-Reactivity: Human, Mouse

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Immunogen: Synthesized peptide derived from C-terminal of Human HARS.

Isotype: IgG

Application Details

Application Notes: WB:1:500-1:3000, IF:1:100-1:500,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for HARS1/Jo-1

Target: HARS1/Jo-1 (HARS1) (Histidyl-tRNA Synthetase (HARS1))

Alternative Name: HARS

Background:

Background: Defects in HARS are a cause of Usher syndrome type 3B (USH3B). USH3B is a syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life. Belongs to the class-II aminoacyl-tRNA synthetase family.

Raben N., Nucleic Acids Res. 20:1075-1081(1992).
Tsui F.W.L., Nucleic Acids Res. 15:3349-3367(1987).
Tsui H.W., Gene 131:201-208(1993).

Aliases: cytoplasmic antibody, EC 6.1.1.21 antibody, FLJ20491 antibody, HARS antibody, HisRS antibody, Histidine tRNA ligase, cytoplasmic antibody, histidine translase antibody, Histidine tRNA ligase antibody, Histidine--tRNA ligase antibody, Histidyl tRNA synthetase antibody, Histidyl-tRNA synthetase antibody, HRS antibody, Human histidyl tRNA synthetase homolog (HO3) mRNA complete cds antibody, SYHC_HUMAN antibody, USH3B antibody

UniProt: P12081